Successful clearance of human parainfluenza virus type 2 viraemia with intravenous ribavirin and immunoglobulin in a patient with acute myocarditis
Successful clearance of human parainfluenza virus type 2 viraemia with intravenous ribavirin and immunoglobulin in a patient with acute myocarditis
复制标题
DOI：
10.1016/j.jcv.2012.10.005
复制
发表时间：
2013-01-01
影响因子：
8.8
通讯作者：
Low, Chian Yong
中科院分区：
文献类型：
--
作者：
Kalimuddin, Shirin;Sessions, October M.;Low, Chian Yong
人类副流感病毒(HPIV)感染作为急性病毒性心肌炎的病原学是罕见的，到目前为止文献中只有很少的病例报道。在这里，我们报告一例暴发性HPIV-2心肌炎，患者为47岁的病毒血症患者，经静脉注射利巴韦林和静脉免疫球蛋白(IVIG)治疗成功。目前还没有关于HPIV心肌炎的治疗建议。据我们所知，我们是第一个报告患有HPIV-2病毒血症的患者，在开始抗病毒治疗后，这种病毒血症后来消失了。虽然很难明确地将患者的临床改善归因于利巴韦林或IVIG，但我们的病例确实表明，临床医生可能希望考虑开始使用利巴韦林和IVIG来治疗HPIV心肌炎和持续性病毒血症患者，这些患者对单独的支持措施没有反应。(C)2012爱思唯尔B.V.保留所有权利。
Human parainfluenza virus (HPIV) infection as an aetiology of acute viral myocarditis is rare, with only few cases reported in the literature to date. Here we report a case of fulminant HPIV-2 myocarditis in a 47 year-old man with viraemia who was successfully treated with intravenous ribavirin and intravenous immunoglobulin (IVIG). There are currently no recommendations on the treatment of HPIV myocarditis. We are, to our knowledge, the first to report a patient with a documented HPIV-2 viraemia that subsequently cleared after the initiation of antiviral therapy. Although it is difficult to definitively attribute the patient's clinical improvement to ribavirin or IVIG alone, our case does suggest that clinicians may wish to consider initiating ribavirin and IVIG in patients with HPIV myocarditis and persistent viraemia not responding to supportive measures alone. (C) 2012 Elsevier B.V. All rights reserved.